Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1007-1011

  Eder, Lihi ^a   Thavaneswaran, Arane ^a   Chandran, Vinod ^a   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BONE EROSION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; MODIFIED STEINBROCKER SCORE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SCORING SYSTEM;

ANTI-TNF; PSORIATIC ARTHRITIS; TNF-ALPHA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899949525     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202959     Document Type: Article

References (20)

1. Rahman P, Nguyen E, Cheung C, et al. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28: 1041-4. (Pubitemid 32422586)
2. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64(Suppl. 2):ii78-82. (Pubitemid 40288529)
3. Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35: 883-90. (Pubitemid 351747132)
4. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68: 702-9.
5. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50: 2264-72. (Pubitemid 38924405)
6. Rinaldi F, Provenzano G, Termini A, et al. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response. Ann Rheum Dis 2005;64: 1375-6. (Pubitemid 41206264)
7. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64: 2504-17.
8. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71: 319-26.
9. Black RL, O'Brien WM, Vanscott EJ, et al. Methotrexate Therapy in Psoriatic Arthritis; double-blind study on 21 patients. JAMA 1964;189: 743-7.
10. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008;27: 823-6.
11. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27: 376-81. (Pubitemid 14134777)
12. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51: 1368-77.
13. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012; 71: 541-8.
14. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 1987;62: 127-41. (Pubitemid 17042878)
15. Rahman P, Gladman DD, Cook RJ, et al. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998;37: 760-5.
16. Eder L, Chandran V, Gladman DD. Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol 2011;38: 1066-70.
17. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008;35: 469-71. (Pubitemid 351374423)
18. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2. Arthritis Rheum 2007;56: 2698-707. (Pubitemid 47237288)
19. Bond SJ, Farewell VT, Schentag CT, et al. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007;66: 370-6. (Pubitemid 46579640)
20. Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.